Sign In
Buy VERX
$12.91
+0.310 (+2.46%)
At Close: Jul 31, 2026
Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets
08:24am, Tuesday, 07'th Jul 2026
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
05:02pm, Monday, 06'th Jul 2026
The acquisition would add to Vertex's pipeline and potentially grow its annual revenue by $5 billion with the addition of Crinetics-developed drugs Palsonify and Atumelnant, the company said.
Vertex Pharma Makes A $10 Billion Deal; Biotech Stock Doubles
04:49pm, Monday, 06'th Jul 2026
Crinetics stock nearly doubled late Monday after Vertex Pharmaceuticals pledged $10 billion to buy the endocrinology-focused biotech company.
Vertex to buy Crinetics in $10 billion deal
04:10pm, Monday, 06'th Jul 2026
Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity value of about $10 billion, the companies said on Monday.
Vertex to Acquire Crinetics Pharmaceuticals
04:04pm, Monday, 06'th Jul 2026
BOSTON & SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, de
Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher?
03:10pm, Monday, 06'th Jul 2026
Vertex's business is growing modestly but there's much more growth potentially on the horizon. The stock's valuation has risen significantly and it's trading far higher than the S&P 500 average.
Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT
11:46am, Thursday, 02'nd Jul 2026
VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autot
US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two
06:45pm, Wednesday, 01'st Jul 2026
The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals' gene therapy in children as young as two with inherited blood disorders, including sickle cell disease, the
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
11:38am, Wednesday, 01'st Jul 2026
Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform. Vertex Pharmaceuticals maintains a dominant market share in cystic fibrosis
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
09:03am, Tuesday, 30'th Jun 2026
Vertex Pharmaceuticals Incorporated maintains a dominant, monopoly position in cystic fibrosis, driving highly predictable, recurring revenue and justifying its valuation premium. VRTX is leveraging i
Why Vertex Stock Is Rising Today
12:01pm, Monday, 29'th Jun 2026
One firm sees room for this tech stock to run.
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
06:00am, Saturday, 27'th Jun 2026
CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Pharmaceuticals offers a profitable portfolio anchored by
Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project
10:00am, Wednesday, 24'th Jun 2026
HOUSTON--(BUSINESS WIRE)-- #BaseOils--Vertex Energy, Inc. (“Vertex” or the “Company”) today announced it is advancing a project at its Mobile, Alabama refinery to produce crude-derived convent
Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade)
09:08am, Wednesday, 24'th Jun 2026
Vertex Pharmaceuticals Incorporated's R&D success extends beyond its cystic fibrosis franchise. VRTX's Povetacicept could be approved by the FDA as early as November 30th for the treatment of an autoi
